Recruitment

Recruitment Status
Active, not recruiting
Estimated Enrollment
2000

Inclusion Criterias

Agreed with written informed consent form
Intervention with Promus PREMIER everolimus eluting coronary stent
Age 20 and more
Agreed with written informed consent form
Intervention with Promus PREMIER everolimus eluting coronary stent
Age 20 and more

Exclusion Criterias

Cardiac shock
Intervention with Promus PREMIER everolimus eluting coronary stent and other drug eluting stent at the same time
Life expectancy of 1year and under
Cardiac shock
Intervention with Promus PREMIER everolimus eluting coronary stent and other drug eluting stent at the same time
Life expectancy of 1year and under

Summary

Conditions
  • Coronary Artery Disease
  • Coronary Disease
  • Heart Diseases
  • Myocardial Ischemia
Type
Observational
Design
  • Observational Model: Cohort
  • Time Perspective: Prospective

Participation Requirements

Age
Between 20 years and 125 years
Gender
Both males and females

Inclusion Criterias

Agreed with written informed consent form
Intervention with Promus PREMIER everolimus eluting coronary stent
Age 20 and more
Agreed with written informed consent form
Intervention with Promus PREMIER everolimus eluting coronary stent
Age 20 and more

Exclusion Criterias

Cardiac shock
Intervention with Promus PREMIER everolimus eluting coronary stent and other drug eluting stent at the same time
Life expectancy of 1year and under
Cardiac shock
Intervention with Promus PREMIER everolimus eluting coronary stent and other drug eluting stent at the same time
Life expectancy of 1year and under

Locations

Daegu
Seoul
Pusan
Seoul
Incheon
...
Daegu
Seoul
Pusan
Seoul
Incheon
Seoul
Cheongju
Cheonan
Yangsan
Anyang
Pusan
Ulsan
Seoul
Pusan
Gangneung
Daejeon
Seoul
Seoul
Uijeongbu
Daegu
Chuncheon
Daejeon
Seoul
Daegu
Kwangju

Tracking Information

NCT #
NCT02060968
Collaborators
  • CardioVascular Research Foundation, Korea
  • Boston Scientific Korea Co. Ltd
Investigators
Not Provided